Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis.

Shroff R, Wan M, Nagler EV, Bakkaloglu S, Cozzolino M, Bacchetta J, Edefonti A, Stefanidis CJ, Vande Walle J, Ariceta G, Klaus G, Haffner D, Schmitt CP; European Society for Paediatric Nephrology Chronic Kidney Disease Mineral and Bone Disorders and Dialysis Working Groups.

Nephrol Dial Transplant. 2017 Jul 1;32(7):1114-1127. doi: 10.1093/ndt/gfx080.

PMID:
28873971
2.
3.

Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease : A meta-analysis.

Hu X, Shang J, Yuan W, Zhang S, Jiang Y, Zhao B, Duan Y, Xiao J, Zhao Z.

Herz. 2017 Aug 23. doi: 10.1007/s00059-017-4605-y. [Epub ahead of print] Review.

PMID:
28835982
4.

Cost-effectiveness analysis of paricalcitol versus calcitriol for the treatment of SHPT in dialytic patients from the SUS perspective.

Menezes FG, Abreu RM, Itria A.

J Bras Nefrol. 2016 Jul-Sep;38(3):313-319. doi: 10.5935/0101-2800.20160048. English, Portuguese.

5.

Prevalence and treatment of hypovitaminosis D in the haemodialysis population of Coventry.

Huish SA, Fletcher S, Dunn JA, Hewison M, Bland R.

J Steroid Biochem Mol Biol. 2016 Nov;164:214-217. doi: 10.1016/j.jsbmb.2016.02.009. Epub 2016 Feb 11.

PMID:
26877202
6.

Effect of Vitamin D Receptor Activators on Glomerular Filtration Rate: A Meta-Analysis and Systematic Review.

Zhang Q, Li M, Zhang T, Chen J.

PLoS One. 2016 Jan 26;11(1):e0147347. doi: 10.1371/journal.pone.0147347. eCollection 2016. Review.

7.
8.

Interventions for metabolic bone disease in children with chronic kidney disease.

Hahn D, Hodson EM, Craig JC.

Cochrane Database Syst Rev. 2015 Nov 12;(11):CD008327. doi: 10.1002/14651858.CD008327.pub2. Review.

PMID:
26561037
9.

Vitamin D & its analogues in type 2 diabetic nephropathy: a systematic review.

Chokhandre MK, Mahmoud MI, Hakami T, Jafer M, Inamdar AS.

J Diabetes Metab Disord. 2015 Jul 15;14:58. doi: 10.1186/s40200-015-0186-6. eCollection 2015.

10.

The Effect of Active Vitamin D on Cardiovascular Outcomes in Predialysis Chronic Kidney Diseases: A Systematic Review and Meta-Analysis.

Li XH, Feng L, Yang ZH, Liao YH.

Nephrology (Carlton). 2015 May 12. doi: 10.1111/nep.12505. [Epub ahead of print]

PMID:
25963841
11.

Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease.

Bover J, Egido J, Fernández-Giráldez E, Praga M, Solozábal-Campos C, Torregrosa JV, Martínez-Castelao A.

Nefrologia. 2015;35(1):28-41. doi: 10.3265/Nefrologia.pre2014.Sep.11796. English, Spanish.

12.

Vitamin D and proteinuria: a critical review of molecular bases and clinical experience.

Pérez-Gómez MV, Ortiz-Arduán A, Lorenzo-Sellares V.

Nefrologia. 2013;33(5):716-26. doi: 10.3265/Nefrologia.pre2013.Apr.12025. Review. English, Spanish.

13.

Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies.

Zheng Z, Shi H, Jia J, Li D, Lin S.

BMC Nephrol. 2013 Sep 25;14:199. doi: 10.1186/1471-2369-14-199. Review.

14.

Active vitamin D treatment for reduction of residual proteinuria: a systematic review.

de Borst MH, Hajhosseiny R, Tamez H, Wenger J, Thadhani R, Goldsmith DJ.

J Am Soc Nephrol. 2013 Nov;24(11):1863-71. doi: 10.1681/ASN.2013030203. Epub 2013 Aug 8. Review.

15.

Topical treatments for chronic plaque psoriasis.

Mason AR, Mason J, Cork M, Dooley G, Hancock H.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3. Review.

PMID:
23543539
16.

Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease.

Han T, Rong G, Quan D, Shu Y, Liang Z, She N, Liu M, Yang B, Cheng G, Lv Y, Stern L.

Biomed Res Int. 2013;2013:320560. doi: 10.1155/2013/320560. Epub 2012 Dec 27.

17.

Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.

Cheng J, Zhang W, Zhang X, Li X, Chen J.

Clin J Am Soc Nephrol. 2012 Mar;7(3):391-400. doi: 10.2215/CJN.03000311. Epub 2012 Jan 5. Review. Erratum in: Clin J Am Soc Nephrol. 2012 Jun;7(6):1053.

18.

Vitamin D compounds for people with chronic kidney disease not requiring dialysis.

Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD008175. doi: 10.1002/14651858.CD008175. Review.

PMID:
19821446
19.

Vitamin D compounds for people with chronic kidney disease requiring dialysis.

Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD005633. doi: 10.1002/14651858.CD005633.pub2. Review.

PMID:
19821349
20.

[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].

Lorenzo Sellares V, Torregrosa V.

Nefrologia. 2008;28 Suppl 3:67-78. Spanish.

Supplemental Content

Loading ...
Support Center